We are live on ! Find out more
TSHA icon

Taysha Gene Therapies
TSHA

63 hedge funds and large institutions have $411M invested in Taysha Gene Therapies in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,435% more capital invested

Capital invested by funds: $9.05M → $411M (+$402M)

218% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 11

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

62% more funds holding

Funds holding: 39 → 63 (+24)

48.17% more ownership

Funds ownership: 21.35% → 69.52% (+48%)

18% more call options, than puts

Call options by funds: $785K | Put options by funds: $663K

Holders
63
Holders Change
+24
Holders Change %
+61.54%
% of All Funds
1%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
35
Increased
14
Reduced
6
Closed
11
Calls
$785K
Puts
$663K
Net Calls
+$122K
Net Calls Change
+$127K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.7M
2
RCM
RA Capital Management
Massachusetts
+$34.5M
3
RI
RTW Investments
New York
+$31.6M
4
VA
VR Adviser
New York
+$27M
5
TCM
TCG Crossover Management
California
+$20.8M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.15M
2
NCM
Nantahala Capital Management
Connecticut
-$827K
3
LCM
Laurion Capital Management
New York
-$775K
4
CC
Carlson Capital
Texas
-$320K
5
Squarepoint
Squarepoint
New York
-$97.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$77.5M +$43.7M +23,378,974 +2,035%
RCM
2
RA Capital Management
Massachusetts
$58.4M +$34.5M +18,472,503 New
RI
3
RTW Investments
New York
$53.4M +$31.6M +16,893,185 New
VA
4
VR Adviser
New York
$45.6M +$27M +14,444,444 New
TCM
5
TCG Crossover Management
California
$35.1M +$20.8M +11,111,111 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$16.8M +$6.98M +3,738,616 +235%
ACA
7
Avoro Capital Advisors
New York
$12.4M +$7.33M +3,925,000 New
ACP
8
Acuta Capital Partners
California
$12.1M +$7.15M +3,827,926 New
AG
9
Artal Group
Luxembourg
$11.6M +$4.15M +2,222,222 +154%
KCM
10
Kynam Capital Management
New Jersey
$10.4M +$6.13M +3,281,313 New
OCA
11
Octagon Capital Advisors
New York
$8.78M +$5.19M +2,777,778 New
PCH
12
Polar Capital Holdings
United Kingdom
$7.99M +$4.73M +2,530,000 New
BBA
13
Baker Bros. Advisors
New York
$7.92M +$4.68M +2,504,756 New
EP
14
Eversept Partners
New York
$5.39M +$3.19M +1,705,774 New
TCM
15
Tybourne Capital Management
Hong Kong
$4.74M – – –
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$4.74M +$2.8M +1,500,000 New
GTC
17
Ghost Tree Capital
New York
$4.19M +$2.47M +1,325,000 New
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$3.94M +$2.33M +1,247,471 New
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$2.96M +$1.75M +936,550 New
Franklin Resources
20
Franklin Resources
California
$2.56M – – –
DC
21
Diametric Capital
Massachusetts
$2.4M +$1.42M +760,014 New
BlackRock
22
BlackRock
New York
$2.36M +$798K +427,043 +133%
SCV
23
Sands Capital Ventures
Virginia
$2.29M – – –
SSA
24
Schonfeld Strategic Advisors
New York
$2.28M +$1.34M +720,043 New
AI
25
Alphabet Inc
California
$2.03M – – –
1
2 3

TSHA Hedge Fund Activity: Q3 2023 in Review

63 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q3 2023, worth a combined $411M — up 4,435% from $9.05M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new TSHA positions and 11 closed out — a net gain of 24 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $43.7M. The largest seller was Millennium Management, exiting entirely with an estimated $1.15M sold.

  • 63 institutional investors held Taysha Gene Therapies (TSHA) as of Q3 2023, up from 39 in Q2 2023.
  • Funds reported $411M of Taysha Gene Therapies stock for Q3 2023, up 4,435% quarter-over-quarter.
  • 35 funds opened new Taysha Gene Therapies positions in Q3 2023 and 11 closed out, a net change of +24 holders.
  • The largest Taysha Gene Therapies buyer in Q3 2023 was Fidelity Investments, an estimated $43.7M added.
  • The largest Taysha Gene Therapies seller in Q3 2023 was Millennium Management, an estimated $1.15M sold.

Based on aggregated 13F filings for Q3 2023.